-

Vetoquinol: 2024 Calendar of Financial Communication

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) published its calendar of financial communication for 2024.

  • January 24, 2024: 2023 Annual revenues (after market)
  • March 20, 2024: 2023 Annual results (confcall after market)
  • April 29, 2024: 2024 First quarter revenues (after market)
  • May 28, 2024: Annual shareholders’ meeting
  • June 6, 2024: Dividend payment
  • September 12, 2024: 2024 First semester results (confcall after market)
  • October 30, 2024: 2024 Third quarter revenues (after market)

Next update: Annual Sales 2023, January 24th, 2024 after market close

ABOUT VETOQUINOL

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the farm animals (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,497 people as of June 30th, 2023.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

More News From Vetoquinol

Vetoquinol: Sales at End September 2025

LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2025, Vetoquinol's (Paris:VETO) sales amounted to €384.2 million, down 3.5% on a reported basis and down 1.3% at constant exchange rates. Over this period, the Group recorded net negative currency impacts of €8.9 million in the Americas and Asia-Pacific/Rest of the World regions and an impact of - €7.7 million from the simplification of complementary ranges, mainly in Europe. Net of these two items, sales for the first nine...

Vetoquinol: 2025 Half Year Results

LURE, France--(BUSINESS WIRE)--Regulatory News: The Board of Directors of Vetoquinol SA (Paris:VETO), meeting on September 9, 2025, approved the financial statements for the first half of the 2025 financial year. The limited review report on the financial statements as of June 30, 2025, was issued by the Statutory Auditors. Vetoquinol's sales amounted to €258 million for the first six months of fiscal year 2025. Sales of Essentials products amounted to €165 million, up 4.2% at constant exchange...

Vetoquinol: Availability of the 2024 Universal Registration Document

LURE, France--(BUSINESS WIRE)--Regulatory News: On 24 April 2025, Vetoquinol (Paris:VETO) filed its 2024 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). The 2024 Universal Registration Document in ESEF and PDF formats (reproduction of the official version of the Universal Registration Document in ESEF format) is available to the public under the conditions provided by applicable regulations and may be consulted on the “...
Back to Newsroom